Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Alimentary Pharmacology & Therapeutics|June 17, 2020
Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis BHyunwoo Oh, Dae Won Jun, I-Heng Lee, et al.Singapore Medical Journal|October 7, 2017
Cost-effectiveness of two-dose human papillomavirus vaccination in SingaporeSun Kuie Tay, Bee-Wah Lee, Woo Yun Sohn, et al.Asian Pacific Journal of Cancer Prevention : APJCP|April 26, 2018
Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in MalaysiaGeorges Van Kriekinge, Woo-Yun Sohn, Syed Mohamed Aljunid, et al.Human Vaccines & Immunotherapeutics|January 12, 2017
Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose scheduleMaria Julieta Germar, Carrie Purugganan, Ma Socorro Bernardino, et al.Journal of Comparative Effectiveness Research|May 10, 2021
Shifting demographics and comorbidity burden in adult Chinese urban patients with chronic hepatitis B, 2013 and 2016Jinlin Hou, Wendong Chen, Ying Han, et al.ACR Open Rheumatology|March 2, 2024
Prevalence and Factors Associated With Patient-Clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced TherapyJeffrey R Curtis, Robert R McLean, I-Heng Lee, et al.Open Forum Infectious Diseases|July 20, 2021
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day MortalitySusan A Olender, Theresa L Walunas, Esteban Martinez, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2020
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of CareSusan A Olender, Katherine K Perez, Alan S Go, et al.Pageof 2